Objective
The discovery of regulatory T cells (Tregs) is a breakthrough in immunology: it revolutionises our understanding of autoimmune disease (AID) pathophysiology and treatment opportunities. Treg numbers or function is defective in most mouse and human AIDs and their restoration induces clinical improvement, as we recently showed using low-dose IL-2 to induce Tregs in patients with AID.
The TRiPoD project is based on 3 well supported assertions:
- Tregs have huge therapeutic potential
- Deep understanding of the Treg T cell receptor (TCR) repertoire is key to exploiting this potential
- Deep sequencing technologies required for this purpose have come of age
TRiPoD aims (i) to decipher the Treg repertoire against insulin and myelin at high resolution, (ii) to discover biomarkers for AIDs, and (iii) to develop therapies based on engineered Tregs.
Deep sequencing of TCRs from insulin- and myelin-specific Tregs generated in vitro will identify dominant TCRs and antigen-specific Treg signatures. These will be analysed during thymocyte differentiation, at steady state and during disease progression, in mice and humans. Their potential as biomarkers (e.g. a Treg TCR specific for insulin for monitoring type 1 diabetes [T1D]) will be tested in experimental models and in clinical trials of IL-2 in T1D and multiple sclerosis (MS).
We will also generate antigen-specific Tregs expressing the dominant TCRs and investigate their therapeutic properties.
Ultimately, TRiPoD will contribute to a better understanding of the pathophysiology of T1D and MS, identify novel biomarkers for the follow-up of patients at high risk of, or with T1D or MS, and generate novel therapeutics for clinical development.
More generally, our results and new approaches developed in TRiPoD should pioneer biomarker discovery and biotherapies in other immunopathologies.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences basic medicine physiology pathophysiology
- medical and health sciences clinical medicine endocrinology diabetes
- medical and health sciences basic medicine neurology multiple sclerosis
- medical and health sciences health sciences infectious diseases RNA viruses HIV
- medical and health sciences basic medicine immunology autoimmune diseases
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
ERC-2012-ADG_20120314
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Host institution
75654 PARIS
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.